Dash R J, Muralidharan R, Talwar V
Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
J Assoc Physicians India. 1999 Apr;47(4):417-25.
Growth hormone therapy with rhGH (recombinant human growth hormone) has been recommended for treatment of GH deficient short stature in children, repeated hypoglycemias in infancy and early childhood due to GH deficiency, short stature accompanying chronic renal failure prior to renal transplantation and Turner's syndrome. It is now increasingly recommended to adults with GH deficiency following pituitary tumour surgery or irradiation or idiopathic hypopituitarism. There are other indications for its use where evidence for protein catabolism is very strong such as burns injury. The end points of GH therapy in children include achievement of desirable adult height or a growth rate velocity of < 2.5 cm/year. In adults GH deficiency, GH therapy is intended for improvement of general well being, body composition and metabolic markers of GH function.
重组人生长激素（rhGH）治疗已被推荐用于治疗儿童生长激素缺乏性身材矮小、婴幼儿期因生长激素缺乏导致的反复低血糖、肾移植前伴有慢性肾衰竭的身材矮小以及特纳综合征。现在越来越多地推荐用于垂体肿瘤手术、放疗后或特发性垂体功能减退的生长激素缺乏成人。在蛋白质分解代谢证据非常确凿的其他情况下也有其使用指征，如烧伤。儿童生长激素治疗的终点包括达到理想的成人身高或生长速度<2.5厘米/年。对于成人生长激素缺乏症，生长激素治疗旨在改善总体健康状况、身体成分和生长激素功能的代谢指标。
